Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...

Gilead Sciences, Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

The EMA’s Committee for Medicinal Products for Human Use (CHMP) determined that expected clinical benefits of seladelpar include delayed development of liver fibrosis and cirrhosis, potentially ...

EMA recommended 17 drugs for marketing authorization in December, including treatments for rare heart conditions, anemia, and liver disease.

Sciences announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive ...

(RTTNews) - Gilead Sciences, Inc. (GILD) announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending ...

Gilead Sciences (NASDAQ:GILD) has received a positive recommendation for approval from European regulators for its drug ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

The U.S. Food and Drug Administration in August granted accelerated approval to seladelpar, which the Foster City, Calif., company markets as Livdelzi. The drug was the key asset in Gilead's $4.3 ...

By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion.

Talk Online Education Group ("51Talk" or the "Company") , a global online education platform with core expertise in English education, announced that its students showcased their talent at the 29th ...

Postmarketing data on obeticholic acid (Ocaliva) identified a risk for serious liver injury in primary biliary cholangitis ...